‘We’re not doing 30 bets a year’: Vijay Pande on betting small after running $4B at a16z
- ID
- 19427
- Status
- summarized
- Published
- 30 Aug 2026, 1:36 AM
- Fetched
- 01 Sep 2026, 1:36 AM
- Provider
- TechCrunch
- Category
- technology
- Original URL
- https://techcrunch.com/2026/08/29/were-not-doing-30-bets-a-year-vijay-pande-on-betting-small-after-running-4-billion-at-a16z/
- Source URL
- https://techcrunch.com/feed/
Summary
- Score
- 4.5
- Created
- 01 Sep 2026, 1:41 AM
- Tags
- Audience
- saas_foundersai_ml_learners
What happened
Vijay Pande, who built a16z's bio fund to nearly $4B, left to start VZVC with Zach Werner—a firm making only a handful of concentrated bets per year, employing no associates, and relying heavily on AI for day-to-day operations. He also highlights a structural problem in AI-driven biotech: unlike text, biological data can't be scraped from the internet, so companies build walled-off datasets, raising questions about who actually benefits from AI advances in medicine.
Why it matters
For founders raising capital, this signals a niche but real shift toward concentrated-check firms that use AI to operate lean with no junior staff—meaning fewer warm-intro gates but also fewer slots. The biotech data point is a concrete reminder that domain-specific AI moats increasingly come from proprietary datasets, not model architecture, which is relevant if you're building vertical AI SaaS in healthcare or other regulated sectors.
Discussion angle
Does the 'AI-operated lean VC' model actually change access for early-stage founders, or does it just concentrate power further among a few partners—and could a Malaysian founder realistically get on a concentrated-bet fund's radar without a Silicon Valley network?